People with chronic wounds deserve more than wound management, they deserve healing.
Omnio’s plasminogen-based therapy accelerates the body’s natural healing process in chronic wounds:
Stopping infection, relieving pain, and restoring tissue where the current standard of care fails.
People with chronic wounds deserve more than wound management, they deserve healing.
Omnio’s plasminogen-based therapy accelerates the body’s natural healing process in chronic wounds:
Stopping infection, relieving pain, and restoring tissue where the current standard of care fails.
Someone loses a limb due to a chronic wound.
An estimated 167 million people with diabetes will develop diabetic foot ulcers (DFUs), and about one-third of these will become hard-to-heal chronic wounds.
Despite best efforts, standard treatments fall short for hard-to-heal diabetic wounds—contributing to amputation in 1 out of every 5 cases.
Healthcare systems in Europe and the US alone spend over €80-90 billion annually treating chronic wounds.
At the forefront of innovation, Omnio is the first to introduce a next-generation therapy powered by a recombinant plasminogen-based drug—stable, scalable, and regenerative
Early feedback from wound care specialists highlights the potential of Omnio’s recombinant plasminogen in patients
with chronic wounds that failed to respond to four weeks of conventional therapy:
Healing from the Inside Out
At the core of Omnio’s therapy is plasminogen — a natural protein that helps your body clear damaged tissue,
fight infection, and regenerate skin. In people with chronic wounds, that healing process stalls.
Omnio restarts it.
Omnio’s preclinical results:
Healing from the Inside Out
At the core of Omnio’s therapy is plasminogen — a natural protein that helps your body clear damaged tissue,
fight infection, and regenerate skin. In people with chronic wounds, that healing process stalls.
Omnio restarts it.
Omnio’s early internal preclinical data and product design suggest that
our recombinant plasminogen has the potential to offer:
Omnio doesn’t just manage wounds. It helps the body heal them.
Chronic Wound Care Market: Valued at approximately USD 18.68 billion in 2025, with projections to reach USD 27.08 billion by 2035
Capturing unmet demand in chronic wound care
Diabetic foot ulcers are one of healthcare’s most urgent and expensive challenges.
Omnio targets the hardest-to-heal cases, where current treatments fail and costs skyrocket.
Our therapy is rooted in biology, supported by decades of research, and built for real-world impact.
The science is solid. The solution is real. The impact is coming.
Patients facing chronic diabetic wound ulcers that resist healing — and the clinicians who work relentlessly to make a difference.
Chronic wounds can rob people of mobility, dignity, and independence.
Omnio is made for those who have tried everything and are still waiting for a real solution.
Omnio’s rec-plg helps patients regain normalcy and purpose.
We begin with diabetic foot ulcers, but our approach applies to a wide range of hard-to-heal wounds.
Chronic wounds should be a thing of the past.
We believe in a future where no one loses their mobility, independence, or quality of life to a wound that won’t heal.
Omnio is working to make that future a reality.
By restoring the body’s natural healing process, we’re not just closing wounds, we’re restoring lives.
Whether you’re a clinician, researcher, or investor, we’re building the future of regenerative healing together.
Omnio is ready to scale. We’re looking for partners who believe in better outcomes for patients and are ready to help us bring this therapy to the people who need it most.
info@omnio.se
Uminova Science Park
Tvistevägen 48 SE- 907 19 Umeå Sweden
LinkedIn